Search
forLearn
5 / 801 resultslearn oligopeptide-71
learn phosphorus
learn phenylanine
learn Biotinyl-GHK
Research
5 / 1000+ results
research Genome-wide association study of atopic and autoimmune comorbidities in alopecia areata
Certain genes may be linked to autoimmune conditions in people with alopecia areata.
research SbbHLH85, a bHLH Member, Modulates Resilience to Salt Stress By Regulating Root Hair Growth in Sweet Sorghum
The SbbHLH85 protein helps sweet sorghum grow more root hairs but makes the plant more sensitive to salt.
research Efficacy and Tolerability of a Topical Gel Containing Mimicking Growth Factors Oligopeptides, Caffeine, Taurine and an Iron-Chelating Complex in Subjects with Androgenetic Alopecia Treated with Topical Minoxidil or Oral Finasteride: a Prospective, 6-Month, Randomized, Assessor-Blinded, 4-Arm, Parallel Group Study
Adding the topical gel improved hair growth more than using minoxidil or finasteride alone.
research Alopecia: from clinic to preclinic and back
Many people suffer from hair loss, which is caused by a disruption in hair growth, and there is a need for personalized treatments and new drugs.
research The Facial Adipose Tissue: A Revision
Different types of facial fat affect aging and treatment outcomes; more research is needed to enhance anti-aging procedures.
Community Join
5 / 1000+ resultscommunity mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Proof DHT is not the main cause of hair loss. TRPS1 Gene and Protein might be. PP405 won’t work. AMP-303 might!
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
community PP405 Identity Research
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.